Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2020 May 15;2(2):95–103. doi: 10.1016/j.bsheal.2020.05.004

Bibliometric analysis of pathogenic organisms

Deqiao Tian 1,
PMCID: PMC7227529  PMID: 38620287

Abstract

Infectious diseases remain as an important public health threat to humans. Research into pathogens can be useful for planning an organized response to infectious diseases. Bibliometric analysis is an important method for scientific research and assessing capability. In this study, 100 pathogens of public health importance were selected, and the distributions of annual, national, institutional, and journal publications on Science Citation Index (SCI) journals were statistically analyzed. The United States of America ranked the first in terms of the number of relevant studies published. China attaches great importance to the prevention and control of infectious diseases, but still needs to improve in the following areas: for example, insufficient SCI reports on particular pathogens, institutions SCI reports on pathogens lower than world top pathogen research institutions, and lack of influential international pathogen-related journals. Scientific literature databases are important tools for science-of-science analysis. The findings of this study shed light on the hot spots and the ignored spots in pathogen researches, and thus would be useful for drawing a national and institutional research plan.

Keywords: Bibliometric analysis, Pathogens, Microorganisms, Parasites, Research, Biosafety, Biosecurity

Highlights

  • Scientific question

  • Scientific literature databases are important tools for science-of-science analysis, which can be referred as Science of the Science of biosafety/biosecurity (SSBS) in the field of biosafety and biosecurity.

  • Evidence before this study

  • In this study, we conducted a comprehensive literature analysis of pathogens, including health-threatening pathogens (HTPs) and biodefense-associated pathogens (BDAPs).

  • New findings

  • Our new findings indicated that some literature on pathogens, particularly BDAPs, showed a decrease followed by an increase. The total number of Science Citation Index reports on pathogens in China is the second highest in the world, but it is significantly behind the number of published studies in the United States. Particularly, SCI reports on BDAPs in China is insufficient, specifically at the university level.

  • Significance of this study

  • The findings of this study highlight the hot spots and ignored spots in pathogen research; therefore, can be helpful on drawing a national and institutional research plan.

1. Introduction

Living standards have continuously been improving on account of the rapid developments in science and technology. Although infectious diseases, in general, have become less common than other diseases such as cancer, cardiovascular disease, metabolic diseases, etc., the frequent genetic transformation of pathogens and the existence of antimicrobial-resistant pathogens are still issues that we have to face today.

During the last few decades, there have been significant advances in the treatment and prevention of infectious diseases, such as HIV, viral hepatitis, and tuberculosis. However, many new infectious diseases have emerged since the SARS epidemic in 2003, such as H5N1 and H7N9 avian influenza, Middle East Respiratory Syndrome, Ebola virus disease, Zika virus disease, Chikungunya virus disease, and the current Coronavirus Disease 2019 (COVID-19). Consequently, human beings are constantly facing the threat of new and re-emerging infectious diseases [1]. In addition to naturally occurring infectious diseases, another danger posed by pathogens is their potential use as biological weapons or in bioterrorism. Large-scale research and development of biological weapons were once carried out in some countries [2]. In 2001, the anthrax mail attack in the United States resulted in significant public panic. Therefore, in recent years, both the United States and United Kingdom have released biosecurity or biodefense national strategies for responding to such threats [3].

Pathogens are defined as microorganisms and parasites that cause infectious and parasitic diseases. At present, there are still many infectious diseases that do not have effective treatments. The development of diagnostic test kits, drugs, vaccines and other countermeasures needs to be based on the full understanding of the biological characteristics and pathogenic mechanisms of these infectious diseases.

Bibliometric analysis is an important method of scientific research assessment. Science-of-science analysis in the field of biosafety and biosecurity can be called Science of Science of biosafety/biosecurity (SSBS). Based on the statistical data of published studies on pathogens, it is possible to gain overall understanding of the worldwide pictures, such as the number of studies on pathogens, the research capability of different countries, the key research institutions, the major journals reporting studies on pathogens, and other parameters of research capability. It is then possible to know the research status, dominant areas, and major gaps, which are important for making strategic plans for scientific research. In the present bibliometric analysis, 100 species of pathogens of public health importance were selected, and the related published literatures were retrieved and statistically analyzed. The findings shed light on the hot spots and ignored spots in pathogen research and can be useful for drawing a national and institutional research plan.

2. Methods

An SCI literature search was performed in November 2018 by using Web of Science and the search scope of SCI-EXPANDED. We examined the titles and screened for article types. The names of pathogens, but not the names of the corresponding disease, were used for the search (Tables 1 –3). Use of the title as the search target can avoid those non-essential studies, but in the same time some studies may have been missed, when compared with the search results using abstracts as the search target. The main purpose of the study is to compare the studies from different years, countries, institutions, and journals, under the same search conditions.

Table 1.

Query key words and comparison by the number of published pathogen studies between China and the United States (bacterial pathogens only).

Order Pathogens Abbreviation Group* Disease Query Article Country-wise distribution United States
China
Sort Quantity Sort Quantity
1 Bacillus anthracis B. anthracis A Anthrax TI = “Bacillus anthracis” 1,722 68 1 1,104 6 59
2 Yersinia pestis Y. pestis A Plague TI = “Yersinia pestis” 1,216 59 1 715 2 137
3 Clostridium botulinum C. botulinum A Botulinum TI = “Clostridium botulinum” 794 56 1 238 12 13
4 Francisella tularensis F. tularensis A Tularemia TI = “Francisellatularensis” 1,039 42 1 634 11 17
5 Brucella spp. Brucella A Brucellosis TI=Brucella 3,132 106 1 713 5 234
6 Burkholderia mallei B.mallei A Glanders TI = “Burkholderia mallei” 141 29 1 97 27 1
7 Burkholderia pseudomallei B. pseudomallei A Melioidosis TI = “Burkholderiapseudomallei” 1,041 54 2 285 11 31
8 Clostridium perfringens C.perfringens A Gas gangrene TI = “Clostridium perfringens” 1,952 69 1 635 8 90
9 Salmonella spp. Salmonella A Food poisoning TI=Salmonella 21,476 160 1 7,306 4 1,282
10 Escherichia coli O157:H7 O157:H7 A Enteric disease TI=O157 AND TI=H7 4,261 93 1 2,226 3 329
11 Shigella Shigella A Enteric disease TI=Shigella 2,283 115 1 692 3 253
12 Staphylococcus Staphylococcus A Skin infections TI=Staphylococcus 27,944 157 1 8,383 3 1,847
13 Vibrio cholerae V. cholerae A Cholera TI = “Vibrio cholerae” 3,151 102 1 1,361 5 156
14 Helicobacter pylori H. pylori B peptic ulcers TI = “Helicobacter pylori” 17,677 153 1 3,386 4 1,433
15 Mycobacterium tuberculosis M. tuberculosis B Tuberculosis TI = “Mycobacterium tuberculosis” 13,511 155 1 4,634 4 1,220
16 Mycobacterium leprae M. leprae B Human leprosy TI = “Mycobacterium leprae” 632 66 1 212 13 14
17 Haemophilus influenzae H. influenzae B Respiratory tract infections TI = “Haemophilus influenzae” 3,116 115 1 1,261 17 54
18 Corynebacterium diphtheriae C. diphtheriae A Diphtheria TI = “Corynebacterium diphtheriae” 230 45 1 79
19 Clostridium tetani C. tetani B Tetanus TI = “Clostridium tetani” 51 27 2 8 9 3
20 Streptococcus pyogenes S. pyogenes B Tonsilitis TI = “Streptococcus pyogenes” 1,597 72 1 490 14 34
21 Streptococcus pneumoniae S. pneumoniae B Respiratory disease TI = “Streptococcus pneumoniae” OR TI = pneumococcus 6,439 127 1 2,350 8 284
22 Streptococcus suis S. suis B meningitis, endocarditis, and arthritis in swine TI = “Streptococcus suis” 920 42 6 67 1 348
23 Neisseria meningitidis N. meningitidis B Septicemia and meningitis TI = “Neisseria meningitidis” OR TI = Meningococcus OR TI = Meningococci 2,206 97 1 562 14 48
24 Neisseria gonorrhoeae N.gonorrhoeae B Gonorrhea TI = “Neisseria gonorrhoeae” OR TI = Gonococcus OR TI = Gonococci 2,029 109 1 887 8 88
25 Bordetella pertussis B. pertussis B Whooping cough TI = “Bordetella pertussis” 1,205 63 1 345 16 29
26 Legionella pneumophila L.pneumophila A Legionnaire's disease TI = “Legionella pneumophila” 1,604 63 1 554 9 61
27 Campylobacter jejuni C. jejuni B Food poisoning TI = “Campylobacter jejuni” 2,958 92 1 850 9 113
28 Borreliella burgdorferi B. burgdorferi B Lyme disease TI = “Borrelia burgdorferi” OR TI = “Lyme disease spirochete” 2,731 72 1 1,640 12 57
29 Treponema pallidum T. pallidum B Pathogenic spirochete TI = “Treponema pallidum” 494 59 1 232 2 78
30 Leptospira Leptospira B Leptospirosis TI = Leptospira 1,555 97 1 392 6 101
31 Listeria monocytogenes L.monocytogenes B Meningitis and sepsis TI = “Listeria monocytogenes” 7,493 95 1 2,525 5 354

* A = Biodefense-associated pathogens (BDAPs), B = Health-threatening pathogens (HTPs).

The selection of the 100 pathogens was based on their historical importance in infectious diseases or their potential impact on humans, in the case of newer pathogens. Several parasitic pathogens, such as those caused malaria and schistosomiasis, were also included. The pathogens were selected from the laboratory biosafety pathogen lists of the National Institutes of Health of the United States, the European Union, and China; the bioterrorism response pathogen lists of the Centers for Disease Control and Prevention of the United States, the European Union, and Russia; and select agent program pathogens listed by the United States [4]. Additionally, the World Health Organization's list of key emerging pathogens for preparedness and response [5], the list of pathogens released by Law of the PRC on the Prevention and Treatment of Infectious Diseases [6], and the pathogens listed in some Chinese textbooks were also referred to [[7], [8], [9], [10]]. The pathogenicity and epidemiologic potential of the pathogens were considered in the selection process.

The selected 100 pathogens were divided into two categories (50 each): biodefense-associated pathogens (BDAPs) and health-threatening pathogens (HTPs)(Table 1, Table 2, Table 3 ). HTPs mainly affect people's health, while BDAPs, which are characterized by rapid and widespread infection, have a serious impact on social stability. We retrieved the relevant literature on the pathogens published from 1995 to retrieval time in 2018. For the annual analysis, we retrieved the literatures published from 1995 to 2017, and used all the literatures for the country-, institution-, and journal-wise analysis based on Web of Science online statistics. The Web of Science literature statistics does not distinguish the first author from the other authors for country-wise and institution-wise analysis, so the cumulative number of studies for each country or institution may higher than the total number of studies.

Table 2.

Query key words and comparison by the number of published pathogen studies between China and the United States (viral pathogens only).

Order Pathogens Abbreviation Group* Disease Query Article Country-wise distribution United States
China
Sort Quantity Sort Quantity
1 Variola virus Variola A Smallpox TI = “Smallpox virus” OR TI = “Variola virus” 72 16 1 35
2 Ebola virus Ebola A Ebola virus disease TI = “Ebola virus” OR TI = ebolavirus 1,641 97 1 996 6 123
3 Marburg virus Marburg A Marburg virus disease TI = “Marburg virus” OR TI = marburgvirus 211 30 1 129 6 12
4 Lassa virus Lassa A Lassa fever TI = “Lassa virus” 156 26 1 82 16 3
5 Venezuelan equine encephalitis virus VEE A Venezuelan equine encephalitis TI = “Venezuelan equine encephalitis virus” 237 25 1 191 23 1
6 Eastern equine encephalitis virus EEE A Eastern equine encephalitis TI = “Eastern Equine Encephalitis virus” 85 10 1 77 2 5
7 Western equine encephalitis virus WEE A Western equine encephalitis TI = “Western equine encephalitis virus” 41 9 1 25 9 1
8 Nipah virus Nipah A Nipah virus infection TI = “Nipah virus” 307 27 1 170 13 6
9 Hendra virus Hendra A Hendra virus disease TI = “Hendra virus” 141 15 2 70 9 4
10 Hantavirus Hantavirus A Hemorrhagic feverpulmonary syndrome TI = “Hantavirus” 1,181 82 1 426 8 64
11 Hantaan virus Hantaan A Hantavirus hemorrhagic fever with renal syndrome (HFRS) TI = “Hantaan virus” 168 19 2 44 1 77
12 Sin Nombre virus SNV A Hantavirus pulmonary syndrome (HPS) TI = “Sin nombre virus” 84 7 1 82
13 Crimean-Congo hemorrhagic fever virus CCHFV A Crimean-Congo hemorrhagic fever TI = “Crimean Congo hemorrhagic fever virus” 245 56 1 66 6 22
14 Rift Valley fever virus RVFV A Rift Valley fever TI = “Rift Valley fever virus” 390 58 1 198 15 8
15 Junin virus Junin A Argentine hemorrhagic fever TI = “Junin virus” 102 14 2 38 6 2
16 Yellow fever virus YFV A Yellow fever TI = “Yellow fever virus” 259 43 1 130 10 8
17 Dengue virus Dengue B Dengue fever TI = “Dengue virus” 3,131 111 1 1,045 6 236
18 Japanese encephalitis virus JEV A Japanese encephalitis TI = “Japanese encephalitis virus” 932 44 5 132 1 202
19 Tick-borne encephalitis virus TBEV A Tick-borne encephalitis TI = “Tick-borne encephalitis virus” OR TI = TBEV 459 49 8 31 20 6
20 West Nile virus WNV A West Nile fever TI = “West Nile virus” 2,802 104 1 1,778 8 70
21 Zika virus Zika B Zika fever TI = “Zika Virus” 1,486 102 1 788 3 144
22 Chikungunya virus Chikungunya B Chikungunya fever TI = “Chikungunya virus” OR TI=CHIKV 849 90 1 260 17 16
23 Severe fever with thrombocytopenia syndrome virus SFTSV B Severe fever with thrombocytopenia syndrome TI = “Severe fever with thrombocytopenia syndrome virus” OR TI = “SFTS virus” 113 14 4 19 1 67
24 Influenza virus Influenza A Influenza TI = “Influenza virus” 6,869 116 1 2,642 2 1,199
25 H5N1 influenza virus H5N1 A Influenza TI=H5N1 AND TI = “Influenza virus” 742 69 1 241 2 223
26 H1N1 influenza virus H1N1 A Influenza TI=H1N1 AND TI = “Influenza virus” 635 60 1 198 2 138
27 H7N9 influenza virus H7N9 A Influenza TI=H7N9 AND TI = “Influenza virus” 89 16 2 29 1 57
28 Measles virus Measles B Measles TI = “Measles virus” 1,317 84 1 480 6 61
29 Rubella virus Rubella B Rubella TI = “Rubella virus” 317 51 1 107 5 25
30 Mumps virus Mumps B Mumps TI = “Mumps virus” 259 37 1 63 5 17
31 Adenovirus Adenovirus B upper respiratory tract infection TI = Adenovirus 9,706 104 1 4,390 2 1,416
32 Respiratory syncytial virus RSV B Upper respiratory tract infection TI = “Human respiratory syncytial virus” OR TI=HRSV 428 63 1 131 4 35
33 Severe acute respiratory syndrome coronavirus SARS A Severe acute respiratory syndrome TI = “SARS Coronavirus” OR TI = “Severe acute respiratory syndrome Coronavirus” OR TI=SARS-CoV 1,394 50 2 481 1 551
34 Middle East respiratory syndrome coronavirus MERS A Middle-East respiratory syndrome TI = “Middle East Respiratory Syndrome Coronavirus” OR TI = “MERS coronavirus” OR TI = MERS-CoV 610 51 1 251 3 138
35 Human immunodeficiency virus HIV B Acquired immunodeficiency syndrome (AIDS) TI = “Human immunodeficiency virus” 17,846 147 1 10,019 11 450
36 Human T-lymphotropic virus HTLV B T-cell leukemia TI = “Human T-lymphotropic virus” OR TI=HTLV 2,680 99 2 814 11 52
37 Hepatitis A virus HAV B Hepatitis A TI = “Hepatitis A virus” 1,088 81 1 221 2 94
38 Hepatitis B virus HBV B Hepatitis B TI = “Hepatitis B virus” 10,712 147 2 2,017 1 3,099
39 Hepatitis C virus HCV B Hepatitis C TI = “Hepatitis C virus” 16,791 151 1 5,335 6 1,077
40 Coxsackievirus Coxsackievirus B Viral myocarditis TI=Coxsackievirus OR TI = “Coxsackie virus” 1,489 61 1 409 2 376
41 Rotavirus Rotavirus B Severe diarrhea TI = Rotavirus 4,723 149 1 1,677 6 257
42 Enterovirus 71 EV71 B Hand-foot-and-mouth disease TI = “Enterovirus 71” OR TI = EV71 1,111 43 3 115 1 569
43 Norwalk virus Norwalk B Gastroenteritis TI=Norovirus OR TI = “Norwalk virus” 2,444 95 1 892 3 201
44 Poliovirus Poliovirus B Polio TI=Poliovirus 1,577 114 1 843 7 62
45 Herpes simplex virus HSV B Gingival stomatitis and neonatal infection, etc. TI = “Herpes simplex virus” 7,544 114 1 3,959 6 336
46 Varicella-zoster virus VZV B Varicella and herpes zoster TI = “Varicella zoster virus” 1,611 78 1 667 14 36
47 Human cytomegalovirus HCMV B Congenital malformation TI=Cytomegalovirus 10,832 113 1 4,170 7 492
48 Epstein-Barr virus EBV B Infectious mononucleosis TI = “Epstein barr virus” 7,497 107 1 2,295 3 746
49 Monkeypox virus Monkeypox A Monkey pox TI = “Monkeypox virus” 82 16 1 70 14 1
50 Rabies virus Rabies B Rabies TI = “Rabies virus” 1,129 92 1 321 2 179
51 Human papillomavirus HPV B Squamous epithelial proliferation of human skin and mucosa TI = “Human papillomavirus” 10,975 147 1 4,383 2 899
52 Human parvovirus B19 B19 B Fetal severe anemia, abortion or death TI = “Human Parvovirus B19” OR TI = “Erythrovirus B19” 423 64 2 73 5 23
53 Foot-and-mouth disease virus FMDV A Foot-and-mouth disease TI = “Foot-and-mouth disease virus” 1,487 86 3 273 2 290
54 African swine fever virus ASFV A African swine fever TI = “African swine fever virus” 416 53 3 73 13 9
55 Newcastle disease virus NDV A Newcastle disease TI = “Newcastle disease virus” 1,317 96 1 371 2 324
56 Vesicular stomatitis virus VSV B Bubbles and erosion of the epithelium of the tongue, lip, oral mucosa TI = “Vesicular Stomatitis” AND TI = Virus 932 46 1 640 3 58

* A = BDAPs; B = HTPs.

Table 3.

Query key words and comparison by the number of published pathogen studies between China and the United States (Rickettsia, Mycoplasma, Chlamydia, fungi, and protozoa).

Order Pathogens Abbreviation Group* Disease Query Article Country-wise distribution United States
China
Sort Quantity Sort Quantity
1 Coxiella burnetii C. burnetii A Q-fever TI = “Coxiella burnetii” 1,055 87 1 292 16 18
2 Rickettsia prowazekii R. prowazekii A Typhus TI = “Rickettsia prowazekii” 95 15 1 69 11 1
3 Rickettsia rickettsii R. rickettsii A Rocky Mountain Spotted Fever TI = “Rickettsia rickettsii” 132 15 1 78 3 6
4 Orientia tsutsugamushi O.tsutsugamushi B Scrub typhus TI = “Rickettsia tsutsugamushi” OR TI = “Orientia tsutsugamushi” 294 28 3 69 6 19
5 Bartonella Bartonella B Trench fever TI=Bartonella 1,504 94 1 706 12 35
6 Mycoplasma pneumoniae M. pneumoniae B Respiratory tract infections TI = “Mycoplasma pneumoniae” 1,289 63 1 287 2 188
7 Chlamydia psittaci C. psittaci A Psittacosis in birds TI = “Chlamydophila psittaci” OR TI = “Chlamydia psittaci” 436 49 1 83 5 35
8 Chlamydia pneumoniae C. pneumoniae B Respiratory infections in people TI = “Chlamydophila pneumoniae” OR TI = “Chlamydia pneumoniae” 1,891 71 1 476 10 66
9 Chlamydia trachomatis C. trachomatis B Disease in either the eye or the urogenital tract TI = “Chlamydia trachomatis” 3,366 119 1 1,316 8 143
10 Coccidioides immitis C. immitis A Coccidioidomycosis TI = “Coccidioides immitis” 134 15 1 124
11 Plasmodium spp. Plasmodium B Human malaria TI=Plasmodium OR TI = “malaria parasite” 16,098 162 1 5,451 15 482
12 Cryptosporidium Cryptosporidium A Diarrhea TI=Cryptosporidium 3,862 114 1 1,602 3 259
13 Schistosome Schistosome B Schistosomiasis TI=Schistosome OR TI = “Blood flukes” 704 78 1 292 3 58

* A = BDAPs; B = HTPs.

3. Results

3.1. Annual number of publications

In this study, a total of 309,624 articles were retrieved. Of these, 295,866 were published in the period 1995–2017, and the highest number of articles (n = 16,658) was published in the year 2006. Based on the trends in the published literatures, three stages were identified: from 1995 to 2002, the increase in the number of published articles was not very remarkable; during 2002 to 2011, the increase was rapid; and during 2011–2017, the increase tended to slow down (Fig. 1 ).

Fig. 1.

Fig. 1

Annual number of published studies on all the pathogens.

We noted that the number of studies for some pathogens showed (1) continuous growth, such as Mycobacterium tuberculosis, Dengue virus, Hepatitis B virus, Norwalk virus, and Plasmodium spp.; (2) a rapid increase followed by a gradual decrease, such as Bacillus anthracis, Yersinia pestis, Ebola virus, H5N1 Influenza virus, H1N1 Influenza virus, H7N9 Influenza virus, SARS coronavirus, and Chlamydia pneumoniae (Fig. 2 ); and (3) a generally decreasing trend. For example, there were 1109 reports on human immunodeficiency virus in 1995, but the number decreased to 471 in 2017.

Fig. 2.

Fig. 2

Annual number of published studies on different pathogens (increase followed by a decrease).

In addition to the above three trends, the reports on other pathogens showed (4) a plateau followed by an increase, such as Zika virus; (5) an increase followed by a plateau, such as Escherichia coli O157:H7; (6) a decrease followed by an increase, such as Vibrio cholerae; (7) a consistent plateau, such as Epstein-Barr virus; (8) a plateau followed by a decrease, such as measles virus; (9) a decrease followed by a plateau, such as poliovirus; and (10) an irregular pattern, mainly for pathogens with a small number of reports (Table 4 , Supplementary Table 1).

Table 4.

Trends by the annual number of published pathogen studies.

Order Trend Pathogens
A Sustained growth Brucella; B. pseudomallei; Salmonella; M. tuberculosis; L.monocytogenes; Hendra; Dengue; SFTSV; HBV; HCV; Norwalk; Rabies; M. pneumoniae; Plasmodium
B Plateau followed by increase S. suis; N.gonorrhoeae; Leptospira; Marburg; Lassa; CCHFV; RVFV; YFV; JEV; TBEV; Zika; Chikungunya; RSV; Coxsackievirus; Rotavirus; EV71; HPV; FMDV; ASFV; NDV; C. burnetii; O. sutsugamushi; C. trachomatis
C Increase followed by plateau F. tularensis; B.mallei; O157:H7; Staphylococcus; S. pneumoniae; L.pneumophila; C. jejuni; WNV; MERS; Cryptosporidium
D Increase followed by decrease B. anthracis; Y. pestis; H. pylori; Ebola; Influenza; H5N1; H1N1; H7N9; SARS; Bartonella; C. pneumoniae
E Decrease followed by increase V. cholerae; T. pallidum
F Plateau C. botulinum; Shigella; M. leprae; H. influenzae; C. diphtheriae; C. tetani; N. meningitidis; B. pertussis; B. burgdorferi; Variola; EEE; WEE; Hantavirus; Rubella; Adenovirus; HAV; VZV; HCMV; EBV; B19; VSV; Schistosome
G Plateau followed by decrease Measles; Mumpsvirus; C. immitis
H Decrease followed by steady HTLV; Poliovirus
I Continued reduction HIV; HSV
G Irregular C.perfringens; S. pyogenes; VEE; Nipah; Hantaan; SNV; Junin; Monkeypox; R. prowazekii; R. rickettsii; C. psittaci

In the case of some pathogens, particularly BDAPs, the literature showed a decrease followed by a rapid increase. For example, after the outbreak of SARS, many studies were focused on vaccine researches and productions [[11], [12], [13]], which were discontinued thereafter. Had the research been continued, the world would have been better prepared for the current COVID-19 pandemic.

3.2. Country and region distributions of pathogen studies

The pathogens with the highest number of published studies were Staphylococcus (27,944), Salmonella (21,476), human immunodeficiency virus (17,846), Helicobacter pylori (17,677), and Hepatitis C virus (16,791). The most common pathogens across countries were Plasmodium (162), Salmonella (160), Staphylococcus (157), Mycobacterium tuberculosis (155), and Helicobacter pylori (153) (Table 1, Table 2, Table 3, Fig. 3 ).

Fig. 3.

Fig. 3

Number of published studies and country/region distribution for each type of pathogen.

The countries/regions with the largest number of published studies on pathogens included the United States of America, China, Japan, England, Germany, France, Canada, Italy, Spain, and India. The United States of America led the highest number of publications on most of the pathogens (82 of the 100 pathogens selected), and also had the second highest number of publications on the following pathogens: Hepatitis B virus, Human T-lymphotropic virus, severe acute respiratory syndrome coronavirus, Burkholderia pseudomallei, Human parvovirus B19, Hendra virus, Hanta Virus, Junin virus, H7N9 Influenza virus, and Clostridium tetani. It had the third and after highest number of publications on the following pathogens: Foot-and-mouth disease virus, Enterovirus 71, African swine fever virus, Orientia tsutsugamushi, severe fever with thrombocytopenia syndrome virus, Japanese encephalitis virus, Streptococcus suis, and tick-borne encephalitis virus.

China had the highest number of published studies on the following pathogens: Hepatitis B virus, Enterovirus 71, severe acute respiratory syndrome coronavirus, Streptococcus suis, Japanese encephalitis virus, Hanta virus, severe fever with thrombocytopenia syndrome virus, and H7N9 Influenza virus. It had also the second highest number of publications on the following pathogens: Adenovirus, Influenza virus, human papillomavirus, Coxsackievirus, Newcastle disease virus, foot-and-mouth disease virus, H5N1 Influenza virus, Mycoplasma pneumoniae, rabies virus, H1N1 Influenza virus, Yersinia pestis, hepatitis A virus, Treponema pallidum, and Eastern equine encephalitis virus. In addition, it had the third highest number of publications on the following pathogens: Staphylococcus, Epstein-Barr virus, Escherichia coli O157:H7, Cryptosporidium, Shigella, Norwalk virus, Zika virus, Middle East respiratory syndrome coronavirus, vesicular stomatitis virus, Schistosoma, and Rickettsia rickettsii.

Japan had the highest number of studies on human T-lymphotropic virus and human parvovirus B19, while England had the highest number of studies on foot-and-mouth disease virus. Further, France had the highest number of studies on Clostridium tetani, while Spain had the highest number of studies on African swine fever virus. For Australia, it was Hendra virus; for Korea, Orientia tsutsugamushi; for Russia, tick-borne encephalitis virus; for Thailand, Burkholderia pseudomallei; and for Argentina, Junin virus (Table 5 ).

Table 5.

Top ranked Countries/regions by number of published studies on various pathogens.

Countries/regions Top-ranked
United States Except: HBV, HTLV, SARS, B. pseudomallei, B19, Hantaan, Junin, H7N9, C. tetani, Hendra (Rank 2); FMDV, EV71, ASFV, O. sutsugamushi (Rank 3); SFTSV; JEV; S. suis; TBEV (Rank after 3)
China S. suis; Hantaan; JEV; SFTSV; H7N9; SARS; HBV; EV71
Japan HTLV; B19
England FMDV
France C. tetani
Spain ASFV
Australia Hendra
Russia TBEV
South Korea O. sutsugamushi
Thailand B. pseudomallei
Argentina Junin

The number of studies exploring various pathogens in the selected 15 countries and regions is shown in Supplementary Table 2. The countries have been selected mainly based on the total number of published studies.

3.3. Top-ranked institutes on published pathogen studies

With regard to the distribution of studies across institutions, the following institutions had the highest number of publications: Pasteur Institute (4,688), Harvard University (4,330), Unites States National Institute of Allergy and Infectious Diseases (NIAID) (3,808), Johns Hopkins University (3,188), University of Washington (3,140), University of Oxford (2,753), University of California San Francisco (2,658), Emory University (2,314), University of Maryland (2,220), and University of Tokyo (2,178). Furthermore, some institutions had the highest number of studies for specific pathogens, such as: Baylor College of Medicine on Helicobacter pylori; Harvard University on human immunodeficiency virus; Chinese Academy of Sciences on severe acute respiratory syndrome coronavirus (Table 6 ).

Table 6.

Institutions with the highest number of published studies on select pathogens.

Countries/regions Institutes Pathogens
United States ARS O157:H7
Baylor Coll Med H. pylori
Colorado State Univ M. leprae
Ctr Dis Control Prevent S. pneumoniae; Variola; EEE; Nipah; CCHFV; WNV; Influenza; Rotavirus; Norwalk; Poliovirus; Monkeypox; Bartonella; Cryptosporidium
Georgia State Univ Rubella
Harvard Univ Staphylococcus; HIV; HSV
Mayo Clin Measles
NCI HPV
NIAID Ebola; C. trachomatis
Northwestern Univ L. pneumophila
Oregon Hlth Sci Univ HCMV
Thomas Jefferson Univ Rabies
Univ Arizona C. immitis
Univ Colorado VZV
Univ Georgia M. pneumoniae
Univ Kentucky Y. pestis
Univ New Mexico SNV
Univ Pittsburgh C. perfringens
Univ S Alabama R. prowazekii
Univ Texas Adenovirus; Zika
Univ Washington T. pallidum
US FDA Mumps
USA (US Army) B. anthracis; B. mallei; VEE
USDA ARS Salmonella
Yale Univ B. burgdorferi; VSV
China Chinese Acad Agr Sci FMDV; NDV
Chinese Acad Sci SARS
Chung Shan Med Univ B19
Fourth Mil Med Univ Hantaan
Fudan Univ HBV
Univ Hong Kong H1N1; H7N9; MERS
Chang Gung Univ (Taiwan of China) EV71
Natl Def Med Ctr (Taiwan of China) JEV
Japan Hokkaido Univ H5N1
Kagoshima Univ HTLV
Natl Inst Infect Dis SFTSV
England Inst Food Res C. botulinum
Univ Birmingham EBV
Univ Oxford H. influenzae; N. meningitidis
Univ York Schistosome
Germany Bernhard Nocht Inst Trop Med Lassa
Univ Marburg Marburg
France INRA Brucella
INSERM HCV
Inst Pasteur Shigella; M. tuberculosis; C. tetani; B. pertussis; L.monocytogenes; RVFV; YFV; Chikungunya
Canada Def Res Dev Canada Suffield WEE
Natl Res Council Canada C. jejuni
Univ British Columbia Coxsackievirus
Univ Montreal S. suis
Spain Inst Salud Carlos III RSV
Univ Autonoma Madrid ASFV
Univ Barcelona HAV
India Natl Inst Cholera Enter Dis V. cholerae
Australia CSIRO Hendra
Sweden Lund Univ S. pyogenes
Orebro Univ Hosp N.gonorrhoeae
Umea Univ F. tularensis
Russia Russian Acad Sci TBEV
Belgium Univ Ghent C. psittaci
Slovakia Slovak Acad Sci C. burnetii
Finland Univ Helsinki Hantavirus
Brazil Univ Estado Rio De Janeiro C. diphtheriae
Univ Sao Paulo Leptospira; R. rickettsii
Argentina Univ Buenos Aires Junin
South Korea Seoul Natl Univ O. sutsugamushi
Thailand Mahidol Univ B. pseudomallei; Dengue; Plasmodium

The number of studies exploring various pathogens by the selected 20 institutions is shown in Supplementary Table 3. The institutions were mainly selected based on the total number of published studies. The list also included some institutions and universities in China, such as the Chinese Academy of Sciences, University of Hong Kong, Fudan University, Chinese Academy of Medical Sciences, Chinese Center for Disease Control and Prevention, and Peking University. “CTR DIS CONTROL PREVENT” ranked the first for its number of published studies. However, as “CTR DIS CONTROL PREVENT” represents the Centers for Disease Control and Prevention of the United States, its published number of studies may come from more than one institution, therefore, it was not selected. The next institution was Pasteur Institute, but studies on influenza virus, severe acute respiratory syndrome coronavirus, and Francisella tularensis were relatively rare. Harvard University was listed next to Pasteur Institute, but studies on Japanese encephalitis virus, Influenza virus, Middle East respiratory syndrome coronavirus, and foot-and-mouth disease virus were relatively rare. The Chinese Academy of Sciences had a relatively high number of studies on Yersinia pestis, Escherichia coli O157:H7, Zika virus, Influenza virus, and severe acute respiratory syndrome coronavirus, and the University of Hong Kong also had a relatively high number of studies on Burkholderia pseudomallei, Helicobacter pylori, influenza virus, severe acute respiratory syndrome coronavirus, and hepatitis B virus. Some universities and institutions in China, such as Fudan University and the Chinese Academy of Medical Sciences, had a small number of studies on BDAPs, such as Bacillus anthracis and Francisella tularensis, in comparison with some universities and institutions in the United States, such as University of Maryland or National Institute of Allergy and Infectious Diseases (NIAID) (Supplementary Table 3).

3.4. Journal distribution of the published studies

With regard to the total number of studies on various pathogens, the following journals had published the highest number of studies: Journal of Virology (14,586), Journal of Clinical Microbiology (7,273), Infection and Immunity (6,885), Journal of Infectious Diseases (5,643), and Vaccine (4,151) (Supplementary Table 4). Some journals had the highest number of studies on some particular pathogens: For example, Emerging Infectious Disease had the highest number of studies on Ebola virus, Infection and Immunity had the highest number of studies on Yersinia pestis, and Vaccine had the highest number of studies on Rotavirus (Table 7 ).

Table 7.

Journals with the highest number of published studies on select pathogens.

Journal country/regions Journals Impact Factor (2018) Pathogens
United States Emerg Infect Dis 7.2 Hantavirus; SNV; MERS
J Virol 4.3 Ebola; Marburg; Lassa; VEE; WEE; Nipah; Hendra; Hantaan; CCHFV; RVFV; Junin; YFV; Dengue; JEV; TBEV; SFTSV; Influenza; H5N1; H1N1; H7N9; Measles; Rubella; Mumps; Adenovirus; RSV; SARS; HIV; HAV; HBV; HCV; Coxsackievirus; Norwalk; Poliovirus; HSV; VZV; HCMV; EBV; Monkeypox; Rabies; HPV; FMDV; ASFV; NDV; VSV
PLoS Negl Trop Dis 4.5 Leptospira; Chikungunya
Antimicrob Agents Chemother 4.7 Staphylococcus; S. pneumoniae
Helicobacter 3.4 H. pylori
J Clin Microbiol 5.0 M. tuberculosis; C. diphtheriae; T. pallidum; Variola; Bartonella; M. pneumoniae
Appl Environ Microbiol 4.1 C. botulinum; C. jejuni
Infect Immun 3.2 Y. pestis; F. tularensis; Brucella; B.mallei; B. pseudomallei; Shigella; H. influenzae; S. pyogenes; N. meningitidis; B. pertussis; L.pneumophila; B. burgdorferi; C. burnetii; R. rickettsii; C. pneumoniae; C. immitis
J Bacteriol 3.2 B. anthracis; V. cholerae; R. prowazekii
PLoS One 2.8 EV71
Am J Trop Med Hyg 2.3 C. tetani; EEE; O. sutsugamushi
Vector Borne Zoonotic Dis 1.9 WNV
J Med Virol 2.0 B19
Sex Transm Dis 2.3 N. gonorrhoeae; C. trachomatis
AIDS Res Hum Retroviruses 1.8 HTLV
J Food Prot 1.6 Salmonella; O157:H7; L.monocytogenes
England Vaccine 4.8 Rotavirus
Sci Rep 4.0 Zika
Malar J 2.8 Plasmodium
Anaerobe 2.7 C. perfringens
Parasitology 2.5 Schistosome
Lepr Rev 0.5 M. leprae
Netherlands Vet Microbiol 2.8 S. suis; C. psittaci
Vet Parasitol 2.0 Cryptosporidium

The number of studies exploring various pathogens for the selected 20 journals is shown in Supplementary Table 4. The journals were selected mainly based on their impact factor and the total number of pathogens studies published. Infection and Immunity and Molecular Microbiology had the highest number of publications on bacterial pathogens; Vaccine had publications on almost all kinds of pathogens; PNAS mainly had reports on viruses; and Emerging Infectious Diseases had more virus-related literature. Some top journals published a number of related studies on particular pathogens: pathogens studies published on Science rank first and second are Plasmodium spp. and Salmonella spp., Nature are Plasmodium spp. and influenza virus; Cell are Plasmodium spp. and Zika virus; New England Journal of Medicine are human immunodeficiency virus and human cytomegalovirus; Lancet are Helicobacter pylori and Hepatitis C virus. (Supplementary Table 4).

4. Discussion

4.1. Characteristics of the retrieved studies

From the quantitative analysis of studies on the selected pathogens, the following characteristics were evidenced:

  • (1)

    The number of studies is closely related to disease epidemics. Some pathogens, such as SARS coronavirus, H1N1 influenza virus, and Ebola virus, have resulted in a rapid increase in the number of studies published after the disease outbreaks. However, once the epidemic has been controlled, the number of studies declined.

  • (2)

    The number of studies was closely related to disease distribution. The number of studies related to pathogens tended to be related to the geographical distribution of the corresponding diseases. For example, the literatures on H7N9 avian influenza is predominate in China, while the most relevant literatures on Burkholderia pseudomallei is in Thailand. In studies assessing Junin virus, it was Argentina which published the most studies.

  • (3)

    Core research institutions play significant roles on pathogen studies. Such as the Pasteur Institute in France, Harvard University, the National Institute of Allergy and Infectious Diseases in the United States, and the Chinese Academy of Sciences.

4.2. Research studies on pathogens in China

China attaches great importance to the prevention and control of infectious diseases; thus has made significant progress in relevant research and biosafety management since the SARS outbreak in 2002–2003 [14]. Although the great advance and progress have been made, improvement in the following areas are still needed:

  • (1)

    Pathogens studied are unbalanced. Relatively large number of published studies is on health-threatening pathogens, such as hepatitis B virus and Japanese encephalitis, while relatively small number of published studies is on biodefense-associated pathogens such as Bacillus anthracis and Ebola virus, specifically at the university level.

  • (2)

    Institutions SCI reports on pathogens lower than world top pathogen research institutions. In the field of pathogen research, national institutions such as the Chinese Academy of Sciences, Chinese Academy of Medical Sciences, and Chinese Center for Disease Control and Prevention play an important role. However, in comparison with the world's top pathogen research institutions such as the Pasteur Institute in France and the National Institute of Allergy and Infectious Diseases in the United States of America, there are still some gap on pathogen research SCI reports.

  • (3)

    The level of Chinese pathogen-related journals needs to be enhanced. It can be seen from the data that the pathogen-related SCI journal are mainly from the United States and Europe. Although the total number of Chinese SCI reports on pathogens is the second largest in the world, there are still not many influential international journals in China in this field.

4.3. Pathogen research is closely related to biosafety and biosecurity

Pathogen researches can protect human health, but it can also create potential biosafety and biosecurity issues that threaten human health.

  • (1)

    The level of research on pathogens is an important index for the ability to deal with infectious diseases. Pathogen research is based on historic infectious diseases, emerging infections, and control of new biological threats. In addition, it is also an important aspect of national biodefense capacity. By strengthening investment in science and technology, China's ability to prevent and control infectious diseases has increased significantly [15]. Consequently, the number of related SCI reports has grown significantly [16], although there is still gaps between China and the United States [17].

  • (2)

    Pathogen research can result in biosafety and biosecurity risks. With the rapid development of life sciences and biotechnology, biosafety and biosecurity issues are receiving increasing attention [[18], [19], [20], [21]]. Pathogen-related researches may lead to an increased likelihood of pathogen laboratory errors, and there is also the possibility of deliberate use by humans [22].

  • (3)

    Towards reducing the biosafety and biosecurity risk, it is necessary to ameliorate the supervision and support for pathogenic researches, including improvement on biosafety management monitoring and risk assessment systems [23]. Furthermore, researches on molecular biocontainment and other methods should also be strengthened [[24], [25]].

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Footnotes

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bsheal.2020.05.004.

Appendix A. Supplementary data

Supplementary material

mmc1.docx (159.1KB, docx)

References

  • 1.Morens D.M., Folkers G.K., Fauci A.S. The challenge of emerging and re-emerging infectious diseases. Nature. 2004;6996:242–249. doi: 10.1038/nature02759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Frischknecht F. The history of biological warfare. EMBO Rep. 2003;4:S47–S52. doi: 10.1038/sj.embor.embor849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tian D.Q., Wang H. Comparison of USA and UK biosecurity and biodefense strategies based on word frequency analysis. Mil. Med. Sci. 2019;7:481–487. doi: 10.7644/j.issn.1674-9960.2019.07.001. [DOI] [Google Scholar]
  • 4.Tian D.Q., Zheng T. Comparison and analysis of biological agent category lists based on biosafety and biodefense. PLoS One. 2014;6 doi: 10.1371/journal.pone.0101163. e101163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.WHO An R&D Blueprint For Action To Prevent Epidemics. https://www.who.int/blueprint/what/improving-coordination/workstream_5_document_on_financing.pdf 2016 (accessed 8 April 2020)
  • 6.Law of the PRC on the Prevention and Treatment of Infectious Diseases http://www.npc.gov.cn/npc/c238/202001/099a493d03774811b058f0f0ece38078.shtml (accessed 28 April 2020)
  • 7.Li F., Xu Z.K. Ninth edition. People’s Medical Publishing House, Beijing; 2018. Medical microbiology. [Google Scholar]
  • 8.Luo E.J. Fifth edition. Science Press; Beijing: 2016. Pathogenic Biology. [Google Scholar]
  • 9.Jin N.Y., Hu Z.M., Feng S.Z. Science Press; Beijing: 2007. New Zoology. [Google Scholar]
  • 10.Jin Q. Science Press; Beijing: 2001. Medical Molecular Virology. [Google Scholar]
  • 11.Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., Nabel G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;6982:561–564. doi: 10.1038/nature02463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gao W.T., Tamin A., Soloff A., D'Aiuto L., Nwanegbo E., Robbins P.D., Bellini W.J., Barratt-Boyes S., Gambotto A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;9399:1895–1896. doi: 10.1016/S0140-6736(03)14962-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., Claire M.St, Murphy B.R., Subbarao K., Collins P.L. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;9427:2122–2127. doi: 10.1016/S0140-6736(04)16501-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gao G.F. For a better world: biosafety strategies to protect global health. Biosaf. Heal. 2019;1:1–3. doi: 10.1016/j.bsheal.2019.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wang Y. The H7N9 influenza virus in China—changes since SARS. N. Engl. J. Med. 2013;25:2348–2349. doi: 10.1056/NEJMp1305311. [DOI] [PubMed] [Google Scholar]
  • 16.Tian D.Q., Zheng T. Emerging infectious disease: trends in the literature on SARS and H7N9 influenza. Scientometrics. 2015;105:485–495. doi: 10.1007/s11192-015-1681-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tian D.Q., Yu Y.Z., Wang Y.M., Zheng T. Comparison of trends in the quantity and variety of Science Citation Index (SCI) literature on human pathogens between China and the United States. Scientometrics. 2012;93:1019–1027. doi: 10.1007/s11192-012-0772-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.National Research Council (US) National Academies Press (US); Washington DC: 2004. Biotechnology Research in an Age of Terrorism. [PubMed] [Google Scholar]
  • 19.National Research Council(US) National Academies Press; Washington DC: 2006. Globalization, biosecurity, and the future of the life sciences. [Google Scholar]
  • 20.Jonathan B. The MIT Press; Cambridge Massachusetts (US): 2012. Tucker, Innovation, dual use and security:managing the risks of emerging biological and chemical technologies. [Google Scholar]
  • 21.Tian D.Q. Bibliometric analysis of the most concerned life science dual-use research literature. Lett. Biotechnol. 2016;5:684–687. doi: 10.3969/j.issn.1009-0002. [DOI] [Google Scholar]
  • 22.Scientific Gryphon. Risk and Benefit Analysis of Gain-of-Function Research, Final Report. 2016. http://www.gryphonscientific.com/wp-content/uploads/2016/04/Risk-and-Benefit-Analysis-of-Gain-of-Function-Research-Final-Report.pdf (accessed 13 April 2017)
  • 23.Zhou D.S., Song H.B., Wang J.W., Li Z.J., Xu S., Ji X.Z., Hou X.X., Xu J.G. Biosafety and biosecurity. J. Biosafety and Biosecurity. 2019;1:15–18. doi: 10.1016/j.jobb.2019.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Langlois R.A., Albrecht R.A., Kimble B., Sutton T., Shapiro J.S., Finch C., Angel M., Chua M.A., Gonzalez-Reiche A.S., Xu K., Perez D., García-Sastre A., Tenoever B.R. MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat. Biotechnol. 2013;9:844–847. doi: 10.1038/nbt.2666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Rovner A.J., Haimovich A.D., Katz S.R., Li Z., Grome M.W., Gassaway B.M., Amiram M., Patel J.R., Gallagher R.R., Rinehart J., Isaacs F.J. Recoded organisms engineered to depend on synthetic amino acids. Nature. 2015;7537:89–93. doi: 10.1038/nature14095. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material

mmc1.docx (159.1KB, docx)

Articles from Biosafety and Health are provided here courtesy of Elsevier

RESOURCES